Tariff Trap: How Trump’s Plan Will Inflate Generic Drug Prices

The proposed tariffs on generic drugs announced by President Donald Trump have sparked a warning from Erez Israeli, CEO of Dr. Reddy’s Laboratories, one of India’s leading pharmaceutical firms. The levies, set to kick in at 100% in August 2028 and rise to 200% a year later, are intended to “onshore” the generic medicine industry to the United States.

However, this plan amounts to a thinly veiled attempt to inflate the price of essential medicines for American patients. Companies like Dr. Reddy’s will pass on the full cost of the levies to consumers, essentially doubling or tripling the prices of generic drugs in the process.

The claim that Trump’s plan benefits American patients by bringing production closer to home is unfounded. Indian firms have long dominated the market for generic medicines due to their low operating costs, which enable them to produce these products at a fraction of the cost of their US-based competitors. As Israeli noted, India has allowed “a significant decrease in the cost of medicine to the United States.”

Instead of addressing this economic reality through tariffs, policymakers should focus on the fundamental issue: that producing generic medicines is a low-margin business, and companies cannot absorb levies of 100% or more without passing them on to consumers. The notion that firms can simply relocate their operations to the US overnight ignores the challenges of establishing new manufacturing facilities and adapting existing supply chains.

Indian Pharmaceutical Alliance data shows that its member companies account for nearly half of generic drug supplies to the US, while industry representatives have noted that these levies are unsustainable. Companies like Dr. Reddy’s already make up a shrinking proportion of their sales in the US market – just 27% this year, down from 50% a few years ago.

Global brokerage Nomura has characterized the economic viability of manufacturing generic medicines in the US as “low,” making relocation by Indian firms all but impossible. Instead, they will increase prices and boost profits at the expense of American patients who rely on these essential medicines.

The future of healthcare in the US looks bleak. As policymakers continue to tinker with the economic incentives driving the generic medicine industry, they risk exacerbating an already dire situation: inflated prices and dwindling access to affordable care. By ignoring the fundamental drivers of supply and demand, Trump’s plan amounts to little more than a thinly veiled handout to pharmaceutical companies at the expense of American patients.

American families will continue to bear the brunt of this ill-conceived plan until policymakers prioritize the needs of patients over corporate profits and re-evaluate their approach to healthcare and economics.